Guggenheim Capital’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-14,100
| Closed | -$481K | – | 1939 |
|
|
2024
Q1 | $481K | Buy |
14,100
+5,005
| +55% | +$149K | ﹤0.01% | 1489 |
|
|
2023
Q4 | $263K | Buy |
+9,095
| New | +$241K | ﹤0.01% | 1723 |
|
|
2023
Q3 | – | Sell |
-13,744
| Closed | -$413K | – | 1913 |
|
|
2023
Q2 | $413K | Buy |
+13,744
| New | +$481K | ﹤0.01% | 1554 |
|
|
2023
Q1 | – | Sell |
-22,360
| Closed | -$798K | – | 2012 |
|
|
2022
Q4 | $798K | Buy |
+22,360
| New | +$777K | 0.01% | 1277 |
|
|
2022
Q3 | – | Sell |
-33,208
| Closed | -$960K | – | 2035 |
|
|
2022
Q2 | $960K | Buy |
+33,208
| New | +$951K | 0.01% | 1247 |
|
|
2021
Q4 | – | Sell |
-7,737
| Closed | -$206K | – | 2219 |
|
|
2021
Q3 | $206K | Sell |
7,737
-5,556
| -42% | -$149K | ﹤0.01% | 2056 |
|
|
2021
Q2 | $409K | Sell |
13,293
-1,255
| -9% | -$38.5K | ﹤0.01% | 1912 |
|
|
2021
Q1 | $381K | Sell |
14,548
-22,846
| -61% | -$639K | ﹤0.01% | 1855 |
|
|
2020
Q4 | $941K | Buy |
37,394
+23,057
| +161% | +$496K | 0.01% | 1373 |
|
|
2020
Q3 | $299K | Sell |
14,337
-4,253
| -23% | -$96.5K | ﹤0.01% | 1639 |
|
|
2020
Q2 | $442K | Sell |
18,590
-1,040
| -5% | -$23K | ﹤0.01% | 1481 |
|
|
2020
Q1 | $354K | Sell |
19,630
-1,650
| -8% | -$34.7K | ﹤0.01% | 1486 |
|
|
2019
Q4 | $505K | Sell |
21,280
-5,735
| -21% | -$139K | ﹤0.01% | 1587 |
|
|
2019
Q3 | $743K | Sell |
27,015
-59,566
| -69% | -$1.76M | 0.01% | 1456 |
|
|
2019
Q2 | $2.87M | Buy |
86,581
+4,242
| +5% | +$145K | 0.02% | 893 |
|
|
2019
Q1 | $2.88M | Buy |
82,339
+8,969
| +12% | +$334K | 0.02% | 904 |
|
|
2018
Q4 | $2.44M | Sell |
73,370
-13,710
| -16% | -$590K | 0.02% | 938 |
|
|
2018
Q3 | $4.38M | Buy |
87,080
+6,521
| +8% | +$322K | 0.03% | 796 |
|
|
2018
Q2 | $4.82M | Sell |
80,559
-19,180
| -19% | -$994K | 0.03% | 747 |
|
|
2018
Q1 | $4.57M | Sell |
99,739
-8,518
| -8% | -$355K | 0.01% | 1069 |
|
|
2017
Q4 | $4.31M | Sell |
108,257
-13,792
| -11% | -$545K | 0.01% | 1121 |
|
|
2017
Q3 | $4.88M | Buy |
122,049
+16,896
| +16% | +$731K | 0.01% | 1078 |
|
|
2017
Q2 | $4.53M | Sell |
105,153
-5,574
| -5% | -$198K | 0.01% | 1081 |
|
|
2017
Q1 | $3.46M | Sell |
110,727
-8,935
| -7% | -$239K | 0.01% | 1247 |
|
|
2016
Q4 | $3.02M | Sell |
119,662
-64,118
| -35% | -$1.43M | 0.01% | 1355 |
|
|
2016
Q3 | $4.54M | Sell |
183,780
-28,614
| -13% | -$648K | 0.01% | 1067 |
|
|
2016
Q2 | $4.33M | Sell |
212,394
-12,277
| -5% | -$218K | 0.01% | 1072 |
|
|
2016
Q1 | $3.43M | Sell |
224,671
-51,206
| -19% | -$668K | 0.01% | 1214 |
|
|
2015
Q4 | $3.71M | Buy |
275,877
+23,132
| +9% | +$358K | 0.01% | 1185 |
|
|
2015
Q3 | $3.55M | Buy |
252,745
+12,209
| +5% | +$227K | 0.01% | 1218 |
|
|
2015
Q2 | $4.08M | Buy |
+240,536
| New | +$3.42M | 0.01% | 1265 |
|
|
2014
Q3 | – | Sell |
-11,187
| Closed | -$122K | – | 3106 |
|
|
2014
Q2 | $122K | Sell |
11,187
-249
| -2% | -$2.22K | ﹤0.01% | 2981 |
|
|
2014
Q1 | $102K | Buy |
+11,436
| New | +$105K | ﹤0.01% | 3026 |
|
Other funds holding SUPN
AC
PCH
SIMG
Guggenheim Capital's SUPN Position: Q2 2024 in Review
Guggenheim Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2024, closing a stake of 14,100 shares — an estimated $481K sold.
Guggenheim Capital first reported a position in SUPN in Q1 2014 and held it in 33 quarters. The position peaked at $4.88M in Q3 2017. 244 funds tracked by Wall St. Rank hold SUPN as of Q2 2024.
- Guggenheim Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- Guggenheim Capital sold 14,100 Supernus Pharmaceuticals shares in Q2 2024, an estimated $481K.
- Guggenheim Capital first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 33 quarters.
- Guggenheim Capital's Supernus Pharmaceuticals position peaked at $4.88M in Q3 2017.
- 244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2024.
Based on Guggenheim Capital's 13F filing for Q2 2024, filed 14 Aug 2024.